glp-1 receptor agonist medication diabetes medications linked to reduced dementia risk GLP-1 Receptor Agonists: From Diabetes

Front Pharmacol 15:1405423

[DOI] [PubMed] [Google Scholar] 53.Izquierdo-Alventosa R., Ingls M., Corts-Amador S., et al

Finally, when compared with placebo, SGLT-2 inhibitors are associated with a robust reduction of hospitalization for HHF and renal outcome, and a moderate reduction of CV and total death, and MACE [13]

This rapid clearance may help prevent the toxic accumulation of mediators in the bloodstream, significantly reducing the severity and duration of systemic MCAS flares, such as flushing, gastrointestinal distress, and neurological inflammation

This is of particular concern in interventions using a multimodal approach of both aerobic and resistance exercise